Press Releases

3 Stocks in Focus: TrueCar, Inc. (TRUE), Galectin Therapeutics, Inc. (GALT), Gentex Corporation (GNTX)


TrueCar, Inc. (TRUE) climbed 0.83% during last trading as the stock added $0.11 to finish the day at $13.34 with about 1.33M shares changing hands, compared to its three month average trading volume of 618.62K. The $1.12B market cap company, which fluctuated between $13.16 and $13.51 during the day, currently situated 201.95% above its 52 week low of $4.42 and -4.1% away from its one year high of $13.91. The RSI of 57.82 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

TrueCar, Inc., together with its subsidiaries, operates as an Internet-based information, technology, and communication services company. The company operates its platform on the TrueCar Website and TrueCar mobile applications. It also customizes and operates its platform for its affinity group marketing partners, including financial institutions, membership-based organizations, and employee buying programs for large enterprises. The company’s platform enables users to obtain market-based pricing data on new and used cars, and to connect with its network of TrueCar certified dealers. In addition, the company provides forecast, consulting, and other services regarding determination of the residual value of an automobile at future given points in time, which are used to underwrite automotive loans and leases, and by financial institutions to measure exposure and risk across loan, lease, and fleet portfolios. Further, TrueCar, Inc. offers geographically specific and real-time pricing information for consumers and dealers. The company was formerly known as Inc. TrueCar, Inc. was founded in 2005 and is headquartered in Santa Monica, California.

Galectin Therapeutics, Inc. (GALT) dropped $-0.33 to close the day at a new closing price of $1.47, a -18.33% decrease in value from its previous closing price that moved the stock 200% above its 52 week low of $0.49. A total of 1.32M shares exchanged hands during the day compared with its three month average trading volume of 381.93K. The stock, which fluctuated between $1.4 and $1.78 during the day, currently situated -51.8% below its 52 week high. The stock is up by 41.35% in the past one month and up by 41.35% over the past three months. With a one year target estimate of $1.12 and RSI of 63.12, the stock still has upside potential, making it a hold for now.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Gentex Corporation (GNTX) had a light trading with around 1.32M shares changing hands compared to its three month average trading volume of 2.2M. The stock traded between $20.41 and $20.6 before closing at the price of $20.51 with -0.44% change on the day. The Zeeland Michigan 49464 based company is currently trading 49.72% above its 52 week low of $13.99 and -6.3% below its 52 week high of $21.89. Both the RSI indicator and target price of 48.5 and $21.1 respectively, lead us to believe that it should be put on hold over the coming weeks.

Gentex Corporation designs, develops, manufactures, and markets automatic-dimming rearview mirrors and electronics for the automotive industry; dimmable aircraft windows for the aviation industry; and commercial smoke alarms and signaling devices for the fire protection industry worldwide. It offers automotive products, including interior and exterior electrochromic automatic-dimming rearview mirrors, automotive electronics, and interior and exterior non-automatic-dimming rearview mirrors with electronic features for automotive passenger cars, light trucks, pick-up trucks, sport utility vehicles, and vans for original equipment manufacturers, tier one automotive mirror manufacturers, and various aftermarket and accessory customers. The company also provides photoelectric smoke detectors and alarms, audible and visual signaling alarms, electrochemical carbon monoxide detectors and alarms, and bells and speakers for use in fire detection systems in office buildings, hotels, and other commercial and residential establishments. Gentex Corporation sells its fire protection products directly, as well as through sales managers and manufacturer representative organizations to fire protection and security product distributors, electrical wholesale houses, and original equipment manufacturers of fire protection systems. The company was founded in 1974 and is headquartered in Zeeland, Michigan.


Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *